GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.44 USD
-0.47 (-1.07%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $43.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Earnings News For GSK
-
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
-
GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance
-
GSK (GSK) Tops Q2 Earnings and Revenue Estimates
-
Glaxo: Q2 Earnings Snapshot
-
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
-
GSK (GSK) Earnings Expected to Grow: Should You Buy?
-
Glaxo (GSK) Up 1.6% Since Last Earnings Report: Can It Continue?
-
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
-
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates
-
Glaxo: Q1 Earnings Snapshot
-
GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
GSK Gears Up for Q1 Earnings: Here's What to Expect
-
Glaxo (GSK) Up 3.1% Since Last Earnings Report: Can It Continue?
-
GSK (GSK) Misses Q4 Earnings Estimates
-
Glaxo: Q4 Earnings Snapshot
-
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
-
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
-
Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?
-
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
-
GSK (GSK) Q3 Earnings and Revenues Surpass Estimates
-
Glaxo: Q3 Earnings Snapshot
-
GSK (GSK) Expected to Beat Earnings Estimates: Should You Buy?
-
GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?
-
Glaxo (GSK) Down 3.9% Since Last Earnings Report: Can It Rebound?
-
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance